Literature DB >> 21130714

Requirement for NBS1 in the S phase checkpoint response to DNA methylation combined with PARP inhibition.

Julie K Horton1, Donna F Stefanick, Jennifer Y Zeng, Michael J Carrozza, Samuel H Wilson.   

Abstract

Treatment of PARP-1-expressing cells with the combination of a DNA methylating agent (MMS) and the PARP inhibitor 4-amino-1,8-naphthalimide (4-AN) leads to an ATR/Chk1-dependent S phase checkpoint and cell death by apoptosis. Activation of ATM/Chk2 is involved in sustaining the S phase checkpoint, and double strand break (DSB) accumulation was demonstrated. NBS1, part of the MRN complex that responds to DSBs, is known to modulate ATR- and ATM-dependent checkpoint responses to UV and IR, but a role in the response to PARP inhibition has not been addressed. Here we show that the S phase checkpoint observed 4-8h after MMS+4-AN treatment was absent in cells deficient in NBS1, but was present in NBS1-complemented (i.e., functionally wild-type) cells, indicating a critical role for NBS1 in this checkpoint response. NBS1 was phosphorylated in response to MMS+4-AN treatment, and this was partially ATR- and ATM-dependent, suggesting involvement of both upstream kinases. NBS1 expression had little effect on ATR-mediated phosphorylation of Chk1 and ATM-mediated phosphorylation of Chk2 in response to MMS+4-AN. Phosphorylation of SMC1 was also observed in response to MMS+4-AN treatment. In the absence of ATM and NBS1, phosphorylation of SMC1 was weak, especially at early times after MMS+4-AN treatment. In the absence of ATR activation, reduced SMC1 phosphorylation was seen over a 24h time course. These results suggested that both ATR and ATM phosphorylate SMC1 in response to MMS+4-AN and that this phosphorylation is enhanced by phospho-NBS1. The loss of the MMS+4-AN-induced S phase checkpoint in NBS1-deficient cells may be due to a reduced cellular level of the critical downstream effector, phospho-SMC1. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21130714      PMCID: PMC3050562          DOI: 10.1016/j.dnarep.2010.11.003

Source DB:  PubMed          Journal:  DNA Repair (Amst)        ISSN: 1568-7856


  40 in total

1.  The Mre11-Rad50-Nbs1 complex acts both upstream and downstream of ataxia telangiectasia mutated and Rad3-related protein (ATR) to regulate the S-phase checkpoint following UV treatment.

Authors:  Erin Olson; Christian J Nievera; Alan Yueh-Luen Lee; Longchuan Chen; Xiaohua Wu
Journal:  J Biol Chem       Date:  2007-05-25       Impact factor: 5.157

2.  ATR signaling mediates an S-phase checkpoint after inhibition of poly(ADP-ribose) polymerase activity.

Authors:  Julie K Horton; Donna F Stefanick; Padmini S Kedar; Samuel H Wilson
Journal:  DNA Repair (Amst)       Date:  2007-02-09

Review 3.  Mre11-Rad50-Nbs1 is a keystone complex connecting DNA repair machinery, double-strand break signaling, and the chromatin template.

Authors:  R Scott Williams; Jessica S Williams; John A Tainer
Journal:  Biochem Cell Biol       Date:  2007-08       Impact factor: 3.626

4.  ATM and the Mre11-Rad50-Nbs1 complex respond to nucleoside analogue-induced stalled replication forks and contribute to drug resistance.

Authors:  Brett Ewald; Deepa Sampath; William Plunkett
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

5.  PARP inhibition during alkylation-induced genotoxic stress signals a cell cycle checkpoint response mediated by ATM.

Authors:  Michael J Carrozza; Donna F Stefanick; Julie K Horton; Padmini S Kedar; Samuel H Wilson
Journal:  DNA Repair (Amst)       Date:  2009-08-31

Review 6.  Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective.

Authors:  Shahneen K Sandhu; Timothy A Yap; Johann S de Bono
Journal:  Eur J Cancer       Date:  2010-01       Impact factor: 9.162

Review 7.  ATM and the Mre11 complex combine to recognize and signal DNA double-strand breaks.

Authors:  M F Lavin
Journal:  Oncogene       Date:  2007-12-10       Impact factor: 9.867

Review 8.  The potential role and application of PARP inhibitors in cancer treatment.

Authors:  Anthony J Chalmers
Journal:  Br Med Bull       Date:  2009-02-09       Impact factor: 4.291

9.  The DNA repair protein NBS1 influences the base excision repair pathway.

Authors:  Daniel Sagan; Romy Müller; Carina Kröger; Arunee Hematulin; Simone Mörtl; Friederike Eckardt-Schupp
Journal:  Carcinogenesis       Date:  2009-01-06       Impact factor: 4.944

10.  DNA polymerase beta and PARP activities in base excision repair in living cells.

Authors:  Aya Masaoka; Julie K Horton; William A Beard; Samuel H Wilson
Journal:  DNA Repair (Amst)       Date:  2009-09-12
View more
  3 in total

1.  Increased PARP-1 association with DNA in alkylation damaged, PARP-inhibited mouse fibroblasts.

Authors:  Padmini S Kedar; Donna F Stefanick; Julie K Horton; Samuel H Wilson
Journal:  Mol Cancer Res       Date:  2012-01-13       Impact factor: 5.852

2.  Differential effects of poly(ADP-ribose) polymerase inhibition on DNA break repair in human cells are revealed with Epstein-Barr virus.

Authors:  Wenjian Ma; Christopher J Halweg; Daniel Menendez; Michael A Resnick
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-09       Impact factor: 11.205

3.  Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations.

Authors:  Konstantin J Dedes; Paul M Wilkerson; Daniel Wetterskog; Britta Weigelt; Alan Ashworth; Jorge S Reis-Filho
Journal:  Cell Cycle       Date:  2011-04-15       Impact factor: 4.534

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.